Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Net Margin (2016 - 2025)

Historic Net Margin for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to 20.84%.

  • Fortress Biotech's Net Margin rose 1236500.0% to 20.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.57%, marking a year-over-year increase of 834700.0%. This contributed to the annual value of 96.91% for FY2024, which is 156500.0% down from last year.
  • As of Q3 2025, Fortress Biotech's Net Margin stood at 20.84%, which was up 1236500.0% from 81.37% recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Net Margin registered a high of 81.37% during Q2 2025, and its lowest value of 341.2% during Q4 2021.
  • Its 5-year average for Net Margin is 133.39%, with a median of 137.06% in 2024.
  • As far as peak fluctuations go, Fortress Biotech's Net Margin crashed by -1665400bps in 2021, and later surged by 1709200bps in 2025.
  • Fortress Biotech's Net Margin (Quarter) stood at 341.2% in 2021, then surged by 48bps to 176.22% in 2022, then surged by 68bps to 56.59% in 2023, then dropped by -13bps to 63.84% in 2024, then surged by 133bps to 20.84% in 2025.
  • Its Net Margin stands at 20.84% for Q3 2025, versus 81.37% for Q2 2025 and 96.77% for Q1 2025.